Liste modèle des médicaments essentiels

Adalimumab

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.	Psoriasis of unspecified type

Benzoyl peroxide

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Cream: 5% ◦ Local > Topical > Lotion: 5%	Acne

Calcipotriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Cream: 50 µg per mL (0.005%) ◦ Local > Topical > Lotion: 50 µg per mL (0.005%) ◦ Local > Topical > Ointment: 50 µg per mL (0.005%)	Psoriasis of unspecified type

Calcitriol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type

Certolizumab pegol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type

Coal tar

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Solution: 5%	Psoriasis of unspecified type

Etanercept

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type

Fluorouracil

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Ointment: 5%	Plantar warts

Infliximab

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to adalimumab pour Psoriasis of unspecified type

Methotrexate

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)	Psoriasis of unspecified type

Podophyllotoxin

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to podophyllum resin pour Plantar warts Therapeutic equivalent to podophyllum resin pour Anogenital warts

Podophyllum resin

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Solution: 10 to 25%	Plantar warts Anogenital warts

Salicylic acid

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Solution: 5%	Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses

Tacalcitol

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation	Therapeutic equivalent to calcipotriol pour Psoriasis of unspecified type

Urea

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Cream: 10%; 5% ◦ Local > Topical > Ointment: 10%; 5%	Xerosis cutis or asteatosis

Ustekinumab

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen	Psoriasis of unspecified type